The estimated Net Worth of Keith A. Goldan is at least $1.07 millió dollars as of 14 June 2024. Mr. Goldan owns over 1,250 units of OptiNose Inc stock worth over $48,413 and over the last 9 years he sold OPTN stock worth over $36,359. In addition, he makes $985,547 as Chief Financial Officer at OptiNose Inc.
Sign up
Mr. Goldan OPTN stock SEC Form 4 insiders trading
Keith has made over 10 trades of the OptiNose Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 1,250 units of OPTN stock worth $25,038 on 14 June 2024.
The largest trade he's ever made was selling 4,617 units of OptiNose Inc stock on 16 March 2022 worth over $9,742. On average, Keith trades about 849 units every 162 days since 2015. As of 14 June 2024 he still owns at least 52,623 units of OptiNose Inc stock.
You can see the complete history of Mr. Goldan stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Keith Goldan biography
Keith A. Goldan CPA serves as Chief Financial Officer of the Company. Mr. Goldan has served as our Chief Financial Officer since January 2017. From March 2015 to January 2017, Mr. Goldan served as Senior Vice President, Chief Financial Officer and Treasurer of Fibrocell Science, Inc., a publicly-traded cell and gene therapy company, and also served as its Corporate Secretary from March 2015 to June 2015. From March 2014 to March 2015, Mr. Goldan served as a financial and operational consultant to companies in the life sciences industry. From November 2008 to March 2014, Mr. Goldan served as Senior Vice President and Chief Financial Officer of NuPathe Inc., a publicly-traded specialty pharmaceutical company that was acquired by Teva Pharmaceutical Industries Ltd. Mr. Goldan previously served as Chief Financial Officer and a member of the board of directors of PuriCore plc, a medical technology company listed on the London Stock Exchange. Earlier in his career, Mr. Goldan served as Vice President and Chief Financial Officer of Biosyn, Inc., a specialty pharmaceutical company, and in a variety of roles with ViroPharma and the Healthcare & Life Sciences Practice of KPMG. Mr. Goldan earned a B.S. in Finance from the Robert H. Smith School of Business at the University of Maryland and an M.B.A. from The Wharton School at the University of Pennsylvania.
What is the salary of Keith Goldan?
As the Chief Financial Officer of OptiNose Inc, the total compensation of Keith Goldan at OptiNose Inc is $985,547. There are 4 executives at OptiNose Inc getting paid more, with Peter Miller having the highest compensation of $2,033,500.
How old is Keith Goldan?
Keith Goldan is 49, he's been the Chief Financial Officer of OptiNose Inc since 2017. There are 11 older and 5 younger executives at OptiNose Inc. The oldest executive at OptiNose Inc is Sandra Helton, 70, who is the Independent Director.
What's Keith Goldan's mailing address?
Keith's mailing address filed with the SEC is 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, , WALTHAM, MA, 02451.
Insiders trading at OptiNose Inc
Over the last 19 years, insiders at OptiNose Inc have traded over $144,654,703 worth of OptiNose Inc stock and bought 116,688 units worth $814,936 . The most active insiders traders include Sriram Venkataraman, Capital Partners Ii Gp, Llc... és Rajat Rai. On average, OptiNose Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,645. The most recent stock trade was executed by Anthony J Krick on 17 July 2024, trading 6,845 units of OPTN stock currently worth $7,803.
What does OptiNose Inc do?
optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo
What does OptiNose Inc's logo look like?
Complete history of Mr. Goldan stock trades at Syndax Pharmaceuticals Inc és OptiNose Inc
OptiNose Inc executives and stock owners
OptiNose Inc executives and other stock owners filed with the SEC include:
-
Peter Miller,
Chief Executive Officer, Director -
Ramy Mahmoud,
President, Chief Operating Officer -
Michael Marino,
Chief Legal Officer and Corporate Secretary -
Peter K. Miller,
CEO & Director -
Keith Goldan,
Chief Financial Officer -
Dr. Ramy A. Mahmoud M.D., M.P.H.,
Pres & COO -
Michael F. Marino,
Chief Legal Officer & Corp. Sec. -
Keith Alan Goldan,
Chief Financial Officer -
Victor M. Clavelli,
Chief Commercial Officer -
Michael F. Marino Esq.,
Chief Legal Officer & Corp. Sec. -
Joseph Scodari,
Independent Chairman of the Board -
Sandra Helton,
Independent Director -
Wilhelmus Groenhuysen,
Independent Director -
William Doyle,
Independent Director -
Jonathan Neely,
VP Investor Relations and Business Operations -
Catherine Owen,
Director -
Victor Clavelli,
Chief Commercial Officer -
Anthony Krick,
VP & Chief Accounting Officer -
Michele Janis MBA,
VP & Acting CFO -
Dr. Per Gisle Djupesland M.D., Ph.D.,
Co-Founder & Chief Scientific Officer of OptiNose AS -
Helena Kyttari Djupesland,
Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway) -
John Messina,
Sr. VP of Clinical Devel. & Medical Affairs -
Karen E. Brophy,
VP of HR -
Paul Mastrapa,
CFO -
John N Kapoor,
Director -
Edward A Blechschmidt,
Director -
Leo Henikoff,
Director -
Kenneth Abramowitz,
Director -
Jerome Sheldon,
Director -
Rajat Rai,
CEO -
Joseph Bonaccorsi,
Secretary -
Richard M Smith,
President & COO -
Capital Partners Ii Gp, Llc...,
-
Ventures Llctkwd Ventures L...,
-
Fund Lp Entrepreneurs Fund ...,
-
Rick Bierly,
Director -
Sriram Venkataraman,
Director -
Larry G Pickering,
Director -
Thomas Edward Gibbs,
Chief Commercial Officer -
Joshua Alexander Tamaroff,
Director -
Robert P O'neil,
Director -
Ventures Llc Wfd,
10% owner -
Ventures Llc Tkwd,
10% owner -
Anthony J Krick,
Chief Accounting Officer -
Tomas J. Heyman,
Director -
Kyle Dempsey,
Director -
Eric Bednarski,
Director -
R John Fletcher,
Director -
Paul Jr. Spence,
Chief Commercial Officer -
Michele Janis,
Acting Chief Financial Officer